Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announced that the company has completed the acquisition of Pollogen Ltd.

“We are excited to welcome the Pollogen team into the Lumenis family,” said Tzipi Ozer-Armon, CEO of Lumenis. “This transaction complements our aesthetic product portfolio and positions Lumenis well in the dynamic beauty market. The addition of Pollogen’s extensive portfolio is key to continuing to provide tailored and innovative beauty solutions to all of our existing and future aesthetic customers.”

Pollogen is an Israeli-based medical aesthetic company, a developer and manufacturer of advanced technologies with full-lines of clinically-proven, non-invasive anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applications. The product platforms include OxyGeneo®, VoluDerm™, Hybrid Energy™, TriPollar®, TriLipo® and TriFractional™.  Pollogen will strengthen Lumenis’ position in the beauty segment with its advanced solutions with a focus on radio-frequency technology.

“This transaction is a positive outcome for our shareholders, employees and customers,” said Zion Azar, co-founder and Chairman of Pollogen. “Over the past 10 years, Pollogen has built a leading position in the aesthetic beauty market based on a culture of innovation and pioneering research. We are thrilled to join the Lumenis team and further develop our products and presence in this rapidly developing market.”